WO2009070924A1 - Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression - Google Patents

Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression Download PDF

Info

Publication number
WO2009070924A1
WO2009070924A1 PCT/CN2007/003400 CN2007003400W WO2009070924A1 WO 2009070924 A1 WO2009070924 A1 WO 2009070924A1 CN 2007003400 W CN2007003400 W CN 2007003400W WO 2009070924 A1 WO2009070924 A1 WO 2009070924A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
group
extract
jujube
glycyrrhizic acid
Prior art date
Application number
PCT/CN2007/003400
Other languages
English (en)
French (fr)
Inventor
Zuoguang Zhang
Original Assignee
Chi, Yu-Fen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2010005840A priority Critical patent/MX2010005840A/es
Priority to EP07845763A priority patent/EP2216040A4/en
Priority to KR1020107012032A priority patent/KR20100091206A/ko
Priority to PCT/CN2007/003400 priority patent/WO2009070924A1/zh
Priority to US12/745,459 priority patent/US20100311674A1/en
Priority to BRPI0722182-7A priority patent/BRPI0722182A2/pt
Application filed by Chi, Yu-Fen filed Critical Chi, Yu-Fen
Priority to CA2746663A priority patent/CA2746663A1/en
Priority to JP2010535193A priority patent/JP5628682B2/ja
Priority to AU2007361992A priority patent/AU2007361992B2/en
Publication of WO2009070924A1 publication Critical patent/WO2009070924A1/zh
Priority to IL206082A priority patent/IL206082A0/en
Priority to ZA2010/04033A priority patent/ZA201004033B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725Ziziphus, e.g. jujube
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Definitions

  • the invention relates to a group of raw materials comprising ginsenoside Rgl, Rbl and glycyrrhizic acid and jujube cyclic adenosine monophosphate (jujube cAMP), and the mechanism of action of the dopa-standard receptor is used for treating depression.
  • the medicine of the disease especially relates to an oral medicine or health food for treating depression caused by clear efficacy, obvious curative effect, high safety for long-term use, and avoiding side effects such as strong vomiting. Background technique
  • Depression is a common disease. According to statistics, about 25% of women in the general population have experienced depression during their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: Modern Psychology) . Data from the World Health Organization (WHO): The incidence of depression in the world is about 11%. There are currently about 340 million people with depression in the world, and this number is still on the rise. The survey found that in the next 20 years, depression It will rise to the second most common disease in the world.
  • WHO World Health Organization
  • the antidepressant drugs are mainly based on Prozac, Serote, Zoloft, etc. (SS-, SN I, NDRI, etc. 5-HT, E, DA reuptake inhibitors), the mechanism of action is Depression is relieved by increasing the amount of serotonin and other components in the human nervous system.
  • the anti-depressant drugs that have been asked have different degrees of side effects, such as: increased suicide rate, headache, dizziness, dizziness, insomnia, lethargy, tinnitus, dry mouth, anorexia, increased appetite, weight gain, blood pressure rise, gastrointestinal Discomfort, nausea, nausea, vomiting, indigestion, diarrhea, constipation, lower limb pain, skin rash, trembling, cramps, sweating, edema, loss of libido, sexual incompetence, etc.
  • anti-depression drugs such as Prozac have become a serious concern in the society.
  • the Food and Drug Administration (FDA) in 2004 asked the pharmaceutical companies to relabel the main 32 anti-depressants on the market.
  • FDA Food and Drug Administration
  • the object of the present invention is to provide a group of oral materials for treating depression by using a raw material containing ginsenoside Rgl, Rbl, glycyrrhizic acid and jujube cAMP to form a multi-target receptor.
  • a raw material containing ginsenoside Rgl, Rbl, glycyrrhizic acid and jujube cAMP to form a multi-target receptor.
  • health foods especially new technical solutions with clear efficacy, obvious curative effect, high safety for long-term use, and no side effects such as strong vomiting.
  • Ginsenoside contains adenylate cyclase (AC) to stimulate adenosine and contains cAMP phosphodiesterase (CAPD) inhibitor; glycyrrhizic acid (glycyrrhetinic acid) is strong cAMP phosphodiesterase (CAPD) Inhibitor.
  • AC adenylate cyclase
  • CAD cAMP phosphodiesterase
  • glycyrrhizic acid glycyrrhetinic acid
  • CAPD cAMP phosphodiesterase
  • ginsenosides and glycyrrhizic acid synergistically can further increase the utilization and activity of cAMP, while the concentration and activity of cAMP can increase the neurotransmission of norepinephrine (NE).
  • NE norepinephrine
  • Qualitative synthesis and release enhance the expression of brain-derived neurotrophic factor (BDNF), inhibit hypothalamic-pituitary-adrenal axis (HPA axis) hyperthyroidism and glucocorticoids Secretion, Thereby achieving significant anti-depressant function.
  • BDNF brain-derived neurotrophic factor
  • HPA axis hypothalamic-pituitary-adrenal axis
  • jujube cAMP can also increase the expression of cAMP in the human body, thereby playing an anti-depressant effect, extracting and purifying jujube cAMP with very small content (about one ten thousandth) in jujube into a large one with 1% jujube cAMP.
  • Jujube extract for anti-test-depressive animal test results show that it has obvious anti-experimental depression function, but only by conventional, for example, water-extracted extraction without further purification to increase the concentration of jujube cAMP in its extract.
  • Jujube extract although containing a small amount of jujube cAMP, does not have obvious anti-test depression function, in order to further enhance the anti-depressant effect of the present invention, jujube cAMP, ginsenoside and glycyrrhizin can also be combined.
  • Ginseng, licorice and jujube are the commonly used medicinal materials and foods for traditional Chinese medicine and dietary supplement diets for thousands of years. In the course of thousands of years of consumption and clinical use, the safety of ginseng, licorice and jujube has been fully proved.
  • the results of human studies and experiments demonstrate that these three herbs do not have significant antidepressant efficacy if they are extracted only by conventionally used methods of decoction, but are not as effective as antidepressants currently used to treat depression;
  • the purification method of the upper column chromatography further increases the concentration of the active ingredients such as ginsenoside Rgl, Rbl and jujube cAMP contained in the extract, and adds a raw material such as glycyrrhizic acid or glycyrrhetinic acid to prepare a medicament for treating depression.
  • ginsenoside Rgl, Rbl, glycyrrhizic acid and jujube cAMP as raw materials to prepare a multi-target receptor for the treatment of depression.
  • a medicine or a health food product in particular, a raw material which is further purified to increase the concentration of ginsenoside Rgl, Rbl and jujube cAMP in the extract, in addition to a solvent such as water or ethanol, and a raw material containing glycyrrhizic acid or glycyrrhetinic acid.
  • Taking the drug reaction can cause side effects such as strong vomiting. Long-term use is safe, has low side effects, and can prevent and improve neurodegenerative diseases and anti-aging.
  • the drug of the present invention differs from the antidepressant drug rolita, which is a known post-receptor mechanism of action, in that it can achieve the same anti-depression effect through the action mechanism of the multi-target receptor, and can avoid the use of rolita. Side effects such as strong vomiting.
  • the conversion rate of glycyrrhizic acid into glycyrrhetinic acid in the human body is almost 100%, and the glycyrrhetinic acid which is more fat-soluble than glycyrrhizic acid can enter the brain through the blood-brain barrier, glycyrrhizic acid inhibits CAPD and has anti-depression effect. It is carried out by in vivo conversion to glycyrrhetinic acid, and therefore, the pharmaceutical composition of the present invention can be processed by using glycyrrhizic acid or oxalic acid as a raw material.
  • the present invention discloses a pharmaceutical composition for treating depression, which is made of a raw material comprising ginsenoside Rgl, Rbl and glycyrrhizic acid or glycyrrhetinic acid.
  • the pharmaceutical composition of the present invention is prepared from a total of 2 to 26 parts by weight of ginsenoside (Rgl + RM ) and 3 to 48 parts by weight of glycyrrhizic acid or glycyrrhetinic acid.
  • the pharmaceutical composition of the present invention is prepared from a total of 4 to 13 parts by weight of ginsenoside (Rgl + Rbl ) and 5 to 16 parts by weight of glycyrrhizic acid or glycyrrhetinic acid.
  • the present invention discloses a multi-target receptor post-action mechanism for treating a pharmaceutical composition
  • a pharmaceutical composition comprising ginsenoside Rgl, Rbl and glycyrrhizic acid or licorice Made from raw materials of acid and jujube cAMP.
  • the pharmaceutical composition of the present invention is composed of 2 to 26 parts by weight including ginsenoside (Rgl+Rbl) and 3 to 48 parts by weight of glycyrrhizic acid or glycyrrhetinic acid and 0.002-0.5 parts by weight of jujube cAMP. production.
  • the pharmaceutical composition of the present invention comprises 4-13 parts by weight of total ginsenosides (Rgl+Rbl), 5-16 parts by weight of glycyrrhizic acid or glycyrrhetinic acid, and 0.01-0.1 parts by weight of jujube cAMP. production.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier or additive, and may be formulated into a tablet, a capsule, a powder, a tablet, a powder, a solution, a microemulsion, a suspension, an emulsion, Oral pharmaceutical dosage forms well known in the art of granules, pills, pills, and the like.
  • the pharmaceutical composition can be used to make medicaments, health foods and nutrients for the treatment of depression.
  • the oral medication for treating depression as described in the specification and claims of the present invention is the core of the object of the present invention.
  • those skilled in the art can according to the theory of traditional Chinese medicine or related modern pharmacology.
  • the above drugs can be routinely added or subtracted or replaced with other traditional Chinese medicine active ingredients (such as Polygala, Bupleurum, Licorice coumarin, etc.) with the same efficacy.
  • Such conventional addition and subtraction and replacement with other CAPD inhibitors, AC initiators or corresponding active ingredients having similar or identical mechanism of action are common technical activities of the skilled artisan and researchers. It is all within the scope of the present invention.
  • FIG. 1 is a schematic view showing the flow of a method for preparing a medicament of Example 1 of the present invention.
  • Fig. 2 is a flow chart showing the process of preparing the medicament of the embodiment 2 of the present invention.
  • Fig. 3 is a schematic flow chart showing the process of preparing the drug of the third embodiment of the present invention.
  • Fig. 4 is a flow chart showing the process of preparing the drug of the fourth embodiment of the present invention.
  • Fig. 5 is a flow chart showing the process of preparing the drug of the fifth embodiment of the present invention.
  • Fig. 6 is a schematic flow chart showing the process of preparing the drug of the sixth embodiment of the present invention. Preferred embodiment of the invention
  • the present invention is primarily directed to the preparation of the medicaments of the present invention in combination with the features of the present invention using methods well known to those skilled in the art.
  • the following examples are for illustrative purposes only and are not intended to limit the invention.
  • the present invention particularly proposes the following technical solutions.
  • the present invention discloses a pharmaceutical composition for treating depression by a multi-target receptor post-action mechanism, which is made of a raw material comprising ginsenoside Rgl, Rbl and glycyrrhizic acid or glycyrrhetinic acid.
  • a pharmaceutical composition for treating depression is prepared by processing a multi-target receptor of the present invention with a raw material containing ginsenoside Rgl, RM, and glycyrrhizic acid or glycyrrhetinic acid.
  • the pharmaceutical composition of the present invention is processed by using 2-26 parts by weight of a total of ginsenosides (Rgl + Rbl) and 3 to 48 parts by weight of glycyrrhizic acid or glycyrrhetinic acid.
  • the pharmaceutical composition of the present invention is processed by using 4 to 13 parts by weight of a total of ginsenosides (Rgl + Rbl ) and 5 to 16 parts by weight of glycyrrhizic acid or glycyrrhetinic acid.
  • a pharmaceutical composition for treating depression is prepared by processing a multi-target receptor of the present invention with a raw material containing ginsenoside Rgl, Rbl, glycyrrhizic acid or glycyrrhetinic acid and jujube cAMP.
  • the pharmaceutical composition of the present invention is processed by using 4-13 parts by weight of total ginsenosides (Rgl + Rbl), 5 to 16 parts by weight of glycyrrhizic acid or glycyrrhetinic acid, and 0.01 to 0.1 parts by weight of jujube cAMP.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier or additive, and may be formulated into a tablet, a capsule, a powder, a tablet, a powder, a solution, a microemulsion, a suspension, an emulsion, a granule, Oral pharmaceutical dosage forms well known in the art of dropping pills, pills, and the like.
  • the pharmaceutical composition of the present invention can be used to prepare medicines, health foods and nutrients for the treatment of depression.
  • Extracting extracts containing ginsenoside Rgl, Rbl and glycyrrhizic acid from ginseng and licorice, or directly using the prepared raw materials containing ginsenoside Rgl, Rbl and glycyrrhizic acid or glycyrrhetinic acid A multi-target receptor post-action mechanism for the treatment of a pharmaceutical composition for depression.
  • a raw material containing ginsenoside (Rgl+Rbl) in total of 2 to 26 parts by weight and 3 to 48 parts by weight of glycyrrhizic acid or glycyrrhetinic acid is processed to prepare a pharmaceutical composition of the present invention.
  • Method three A raw material containing ginsenoside (Rgl+Rbl) in total of 2 to 26 parts by weight and 3 to 48 parts by weight of glycyrrhizic acid or glycyrrhetinic acid is processed to prepare a pharmaceutical composition of the present invention.
  • ginseng saponins Rgl, Rbl, glycyrrhizic acid and jujube cAMP from ginseng and licorice and jujube, or directly using ginsenoside Rgl, Rbl, glycyrrhizic acid or glycyrrhetinic acid
  • the raw material of jujube cAMP is processed into a multi-target receptor of the present invention to act as a pharmaceutical composition for treating depression.
  • a raw material containing 2 to 26 parts by weight of ginsenoside (Rgl + Rbl), 3 to 48 parts by weight of glycyrrhizic acid or glycyrrhetinic acid, and 0.002 to 0.5 parts by weight of jujube cAMP is processed to prepare a pharmaceutical composition of the present invention.
  • a raw material containing 4 to 13 parts by weight of ginsenoside (Rgl + Rbl ), 5 to 16 parts by weight of glycyrrhizic acid or glycyrrhetinic acid, and 0.01 to 0.1 part by weight of jujube cAMP is processed to prepare a pharmaceutical composition of the present invention.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier or additive, and may be used as a tablet, a capsule, a powder, a tablet, a powder, a solution, a microemulsion, a suspension, an emulsion, a granule. Any of the pharmaceutically acceptable oral dosage forms, such as agents, pills, pills, and the like.
  • the raw material according to the present invention is processed into a health food for treating depression according to the method for producing a health food.
  • FIG. 1 is a schematic flow chart of a method for preparing the drug of the embodiment 1 of the present invention.
  • 20 kg of ginseng is firstly crushed and then extracted with 70% ethanol solution, and purified by column chromatography, and dried to obtain 0.8 g of ginseng extract containing 120 g of ginsenoside (Rgl + Rbl); Then, 10 kg of licorice was crushed and immersed at room temperature for 12 hours, extracted by water extraction and alcohol precipitation, and concentrated and dried to obtain 2 kg of licorice extract containing 200 g of glycyrrhizic acid; then, the ginseng extract 150 obtained by the above method was obtained.
  • g and licorice extract 200 g were pulverized and mixed uniformly to obtain 350 g (containing 22.5 g of ginsenoside Rgl + Rbl and 20 g of glycyrrhizic acid) of the pharmaceutical composition of the first aspect of the present invention.
  • FIG. 2 is a schematic flow chart of a method for preparing the medicament of the embodiment 2 of the present invention.
  • Fig. 2 3.96 g of glycyrrhetinic acid prepared to have a purity of 96% and 200 g of the ginseng extract obtained in Example 1 were pulverized and mixed uniformly to obtain 203.96 g (containing 30 g of ginsenoside Rgl+Rbl and 3.8 g).
  • Glycyrrhetinic acid A pharmaceutical composition of the second aspect of the invention.
  • FIG. 3 is a schematic flow chart of a method for preparing the drug of Example 3 of the present invention.
  • 3.4 g of ginsenoside Rgl with a purity of 90%, 7.8 g of ginseng scorpion Rbl with a purity of 90%, and 36.8 g of glycyrrhizic acid with a purity of 95% are pulverized and mixed to obtain 48 g.
  • Pharmaceutical composition of the third embodiment of the present invention comprising 10 g of ginsenoside Rgl + Rbl and 35 g of glycyrrhizic acid).
  • FIG. 4 is a schematic flow chart of a method for preparing the drug of Example 4 of the present invention.
  • 10 kg of jujube is broken, water is added at room temperature, and then extracted by water extraction and alcohol precipitation to obtain jujube The liquid was taken out, and then the macroporous resin OU-2 and ME-2 were successively subjected to adsorption separation and drying on the upper column, and 30 g of jujube extract containing jujube cAMP 0.3 g was obtained as a raw material for preparing the medicament of the present invention.
  • FIG. 5 is a schematic flow chart of a method for preparing the drug of the embodiment 5 of the present invention.
  • 150 g of the ginseng extract obtained in Example 1 and 200 g of the licorice extract and 0.5 g of the jujube extract obtained in Example 4 were pulverized and mixed to obtain 350.5 g (containing 22.5 g of ginsenoside Rgl + bK). 20 g of glycyrrhizic acid and 0.005 g of jujube cAMP)
  • the pharmaceutical composition of the fifth aspect of the invention 150 g of the ginseng extract obtained in Example 1 and 200 g of the licorice extract and 0.5 g of the jujube extract obtained in Example 4 were pulverized and mixed to obtain 350.5 g (containing 22.5 g of ginsenoside Rgl + bK). 20 g of glycyrrhizic acid and 0.005 g of jujube cAMP)
  • FIG. 6 is a schematic flow chart of a method for preparing the drug of the embodiment 6 of the present invention.
  • Fig. 6 6.8 g of ginsenoside Rgl having a purity of 90%, 15.6 g of ginsenoside Rbl having a purity of 90%, 26 g of glycyrrhetinic acid having a purity of 96%, and jujube obtained in Example 4 were prepared.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 1 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 1 High dose: 80 mg/kg/d, medium dose: 40 mg/kg/d and 4 dose: 20 mg/kg/d.
  • mice were randomized into groups of 10: 1. Example 1 high dose group (80 mg/kg, PO, 7d administration); 2. Example 1 dose group (40 mg/kg, PO, administration) 7d); 3. Example 1 low dose group (20 mg / kg, PO, 7d administration); 4. Paroxetine group (3 mg / kg, PO, 7d); 5. Saline group (PO) .
  • a tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was glued to the wooden strip with a head height of 5 cm.
  • Example 1 of the present invention has an anti-experimental depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • thermometer GM222 type electronic thermometer, stopwatch.
  • Example 1 High dose: 80 mg/kg/d, medium dose: 40 mg kg/d and 4 dose: 20 mg/kg d.
  • mice were randomized into groups of 10: 1. Example 1 high dose group (80 mg/kg, PO, 7d administration); 2. Example 1 dose group (40 mg/kg, PO, administration) 7d); 3. Example 1 low dose group (20 mg / kg, PO, 7d administration); 4. Paroxetine group (3 mg / kg, PO, 7d); 5. Saline group (PO) .
  • the anus temperature of the mice was measured 1 hour after the administration on the 8th day, and then the reserpine 2 mg kg was intraperitoneally injected, and the anal temperature of the mice was measured 4 hours after the injection of the reserpine.
  • the depth and time of insertion of the thermometer into the anus of the mouse were consistent at each temperature measurement.
  • the high, middle and low dose groups and the paroxetine group of the embodiment 1 of the invention can significantly reduce the blood temperature drop induced by reserpine, indicating that the anti-experimental depression effect may affect the monoamine delivery.
  • the content of the substance is related, so that it can be inferred that the embodiment 1 of the present invention has an anti-solid depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Real Animal Science, Beijing Capital Medical University.
  • Example 2 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • mice were randomized into groups of 10: 1. Example 2 high dose group (80 mg/kg, PO, 7d administration); 2. Example 2 dose group (40 mg/kg, PO, administration) 7d); 3. Example 2 low dose group (20 mg/kg, PO, 7d administration); 4. Paroxetine group (3 mg/kg, PO, 7d administration); 5. Physiological salt ice group (PO) ).
  • a tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was adhered to the 5 cm wooden strip with a tape on the head for 6 minutes, and the immobility time of the mouse within 5 minutes after the recording was recorded.
  • the experimental data were expressed by ⁇ S£>, and the experimental results were analyzed by SPSS 11.5 statistical software for analysis of variance.
  • Example 2 Medium dose group 10 76.21 ⁇ 28.36*
  • Example 2 of the present invention has an anti-experimental depression function.
  • Experimental Example 4 Effect of Example 2 on the Decrease in Temperature of Mouse Reserpine Induced
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 2 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • thermometer GM222 type electronic thermometer, stopwatch.
  • Example 2 High dose: 80 mg/kg/d. Medium dose: 40 mg/kg/d and low dose: 20 mg kg/d.
  • mice were randomly divided into groups of 10: 1, high dose group of Example 2 (80 mg kg, PO, 7d administration); 2. dose group of Example 2 (40 mg/kg, PO, administration for 7 days) 3.
  • Example 2 low dose group (20 mg/kg, PO, 7d administration); 4.
  • Paroxetine group (3 mg/kg, PO, 7d administration); 5.
  • the anus temperature of the mice was measured 1 hour after the administration on the 8th day, and then the reserpine 2 mg/kg was intraperitoneally injected, and the anal temperature of the mice was measured 4 hours after the injection of reserpine.
  • the depth and time of insertion of the thermometer into the anus of the mouse were consistent at each temperature measurement.
  • the dose group and the paroxetine group in the examples of the present invention can significantly reduce the hypothermia-induced hypothermia, indicating that the anti-experimental depression effect may be related to the influence of the monoamine-tending shield, thereby being inferred.
  • Inventive Example 2 has an anti-experimental depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 3 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 3 High dose: 80 mg kg/d, medium dose: 40 mg/kg/d and low dose: 20 mg kg/d.
  • mice were randomized into groups of 10: 1. Example 3 high dose group (80 mg/kg, PO, 7d administration); 2. Example 3 dose group (40 mg/kg, PO, administration) 7d); 3. Example 3 low dose group (20 mg / kg, PO, 7d); 4. Paroxetine group (3 mg / kg, PO, 7d); 5. Saline group (PO) .
  • a tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was adhered to the 5 cm wooden strip with a tape on the head for 6 minutes, and the immobility time of the mouse was recorded within 5 minutes after the recording.
  • Group J animals number (only) immobility time (seconds) saline group (model group) 10 113.22 ⁇ 21.18 paroxetine group 10 75.33 ⁇ 22.91*
  • Example 3 of the present invention has an anti-experimental depression function.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 3 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • thermometer GM222 type electronic thermometer, stopwatch.
  • Example 3 High dose: 80 mg/kg/d, medium dose: 40 mg/kg/d and low dose: 20 mg/kg/d.
  • mice were randomized into groups of 10: 1, high dose group of Example 3 (80 mg/kg, PO, 7d administration); 2. dose group of Example 3 (40 mg/kg, PO, administration) 7d); 3. Example 3 low dose group (20 mg / kg, PO, 7d); 4. Paroxetine group (3 mg / kg, PO, 7d); 5. Saline group (PO) .
  • the anus temperature of the mice was measured 1 hour after the administration on the 8th day, and then the reserpine 2 mg/kg was intraperitoneally injected, and the anal temperature of the mice was measured 4 hours after the injection of reserpine.
  • the depth and time of insertion of the thermometer into the anus of the mouse were consistent at each temperature measurement.
  • Example 3 Effect of Example 3 on the decrease of body temperature induced by reserpine in mice
  • mice Group animals (only) Body temperature drop (V) Saline group (model group) 10 3.65 ⁇ 0.77 Paroxetine group 10 2.38 ⁇ 0.69**
  • the high, middle and low dose groups and the paroxetine group of the present invention can significantly reduce the hypothermia-induced hypothermia, indicating that the anti-experimental depression may affect the monoamine delivery.
  • the content of the substance is related, so that it can be inferred that the embodiment 3 of the present invention has an anti-experimental depression work f3 ⁇ 4.
  • Olfactory bulb damage model Healthy Wistar male rats, secondary, weight 330 soil 20 g, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Certificate No. SCXK (Beijing) 2002-0003).
  • Example 4 was supplied by Onar Bioengineering Technology Co., Ltd. (batch number: 060313), paroxetine was produced by Sino-US Tianjin Shike Pharmaceutical Co., Ltd. (batch number: 0405001 1 ), and the above drugs were treated with 0.5% carboxymethylcellulose ( CMC-Na) is used for intragastric administration; penicillin sodium for injection is the product of Huabei Pharmaceutical Co., Ltd. (batch number: S051 1204); norepinephrine (NE) and serotonin (5-HT) standard products are Sigma Products; Other reagents are commercially available.
  • CMC-Na carboxymethylcellulose
  • NE norepinephrine
  • 5-HT serotonin
  • Rats were randomly divided into 6 groups, sham operation group, model control group, Example 4 high dose group (60 mg/kg/d), Example 4 medium dose group (30 mg/kg/d), and Example 4 low dose. Group (15 mg/kg d ), paroxetine group (2 mg/kg d).
  • the test drug was prepared with a positive pharmaceutical 0.5% carboxymethylcellulose (CMC-Na). Administered once a day.
  • Rats were anesthetized with chloral hydrate. After anesthesia, they were incised from 1 cm in front of the anterior gate of the rat to 1 cm in the median line of the anterior bronchi, exposing the skull. At the distance of 8 mm from the front bony and 2 mm on both sides of the median line, the open bone window is about 2 mm in diameter.
  • the special electric soldering iron was inserted vertically into the cranium for 2 seconds to destroy the olfactory bulb, and the skin was sutured with hemostatic sponge.
  • the intraperitoneal injection (intraperitoneal, IP) was given 40,000 units/kg of penicillin sodium every 4 days after continuous administration. The test drug was given for 24 days.
  • the open field experiment box consists of light blue plywood and aluminum alloy frame (1 m X 1 m X 0.4 m), and the bottom of the box is divided into 25 squares (20 cm x 20 cm each), with the outer walls along the four walls, and the rest Central grid. Place the animals in the middle square and observe the number of crossings of the animals within 3 minutes (three or more crossings into the adjacent grid) and the number of standings (both forelimbs more than 1 cm above the ground).
  • ⁇ Real ⁇ The box consists of two chambers, bright and dark. There is a passage for rats to enter and exit.
  • the darkroom grille is connected with the electric shock meter. There is a movable partition between the two chambers. If the rat enters the dark room, it is shocked.
  • the head of the rat was placed in the bright room for 5 minutes, and then the separator was taken out for 5 minutes to record the time when the rat first entered the dark room (electric shock latency), which is the academic achievement. After 24 hours, the test was repeated, and the separator was withdrawn and energized for 5 minutes to observe the time when the rat first entered the darkroom, which was a memory score.
  • the experimental data was represented by iS, and the experimental results were analyzed by SPSS 11.5 statistical software for analysis of variance.
  • Example 7 The results of Experimental Example 7 show that the high dose group of Example 4 can significantly improve the horizontal and vertical movement of rats caused by olfactory bulb damage.
  • the dose group of Example 4 also significantly improved the vertical movement of rats with olfactory bulb destruction.
  • the high and middle dose groups of Example 4 caused damage to the olfactory bulb. Rat learning and memory dysfunction also improved significantly.
  • Unpredictable long-term stress model healthy Wistar male rats, secondary, weighing 240 ⁇ 270 g, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Certificate No. SCXK (Beijing) 2002-0003).
  • Example 4 was supplied by Onar Bioengineering Technology Co., Ltd. (batch number: 060313), paroxetine was produced by Sino-US Tianjin Shike Pharmaceutical Co., Ltd. (batch number: 04050011), and 0.5% carboxymethyl cellulose (CMC) was used for the above drugs.
  • CMC carboxymethyl cellulose
  • -Na) is used for intragastric administration after preparation; penicillin sodium for injection is product of Huabei Pharmaceutical Co., Ltd. (batch number: S0511204); norepinephrine (NE) and serotonin (5-HT) standard products are products of Sigma; Other reagents are commercially available.
  • Rats were randomly divided into 6 groups, sham operation group, model control group, Example 4 high dose group (60 mg/kg/d), Example 4 medium dose group (30 mg/kg/d), and Example 4 low dose. Group (15 mg kg/d) > paroxetine group (2 mg/kg/d).
  • the test drug was prepared with a positive pharmaceutical 0.5% carboxymethyl cellulose (CMC-Na). Administered once a day.
  • Unpredictable long-term stress model The blank control group received normal drinking water without any irritation.
  • One stimulus was given at random every day for 24 days. Each stimulus should not be given continuously. Administered once a day for 24 days.
  • the experiment was carried out in two days after the last administration. On the first day, pre-test for 15 minutes, the glass cylinder is filled with 25 °C warm water and the water depth is 25 cm. After 24 hours, a formal experiment was conducted, and one hour after the administration, the rats were placed in the middle, and the immobility time was observed and recorded for 5 minutes.
  • the contents of NE and 5-HT in rat cerebral cortex were determined.
  • Example 4 high dose group 13 only 22.55 ⁇ 5.03 The dose group 13 in Example 4 was only 26.53 ⁇ 4.99 **
  • Example 4 Low dose group 13 26.97 ⁇ 6.93 ** Paroxetine group 13 26.29 ⁇ 4.87 ** Model group 13 19.42 ⁇ 4.25 Blank control group 13 29.41 + 3.83 ** Note: Compared with the model group *P ⁇ 0.05 **P ⁇ 0.01
  • Example 4 High dose group 12 230.4157 ⁇ 47.78554* 269.5409 ⁇ 58.86389** The dose group 12 in Example 4 303.4418 ⁇ 70.31711** 227.2976 ⁇ 28.95101**
  • Example 4 low dose group 12 332.7343 ⁇ 76.25168** 201.8688 ⁇ 29.80775**
  • Example 8 showed that the low dose group in Example 4 can significantly improve the unpredictable long-term stress stimulation caused by the reduction of sucrose water consumption and weight loss; the high, medium and low dose groups of Example 4 can significantly increase the forced swimming of rats.
  • Example 4 high dose group can significantly improve the unpredictable long-term stress stimulation caused by the reduction of horizontal and vertical movement of rats, the low dose group of Example 4 caused by unpredictable long-term stress stimulation The reduction of vertical movement of rats also had a significant improvement effect;
  • Example 4 The dose group improved the learning ability of rats caused by unpredictable long-term stress stimulation;
  • Example 4 high and low dose groups can significantly increase the cerebral cortex of rats. E and 5-HT content.
  • Example 5 was provided by O'Neill Bioengineering Technology Co., Ltd. (a pilot-scale product); Paroxetine was a product of Sino-US Tianjin Shike Pharmaceutical Co., Ltd. (batch number: 05070384), and the above drugs were formulated with physiological saline for intragastric administration.
  • mice ICR mice, male, weighing 20.0 ⁇ lg, secondary, provided by the Department of Health - Risk Animal Science, Peking University Medical Department, animal quality certificate number SCXK (Beijing) 2006-0008.
  • mice Seventy mice were randomly divided into 5 groups, NS group, paroxetine group (3 mg/kg/d), Example 5 high dose group (80 mg/kg/d), and Example 5 medium dose group (40 mg). /kg/d), Example 5 low dose group (20 mg/kg/d).
  • the drug was administered once a day, and the tail end of the mouse (1 cm from the tip of the tail) was glued to a horizontal support placed in an open box 1 hour after the administration on the eighth day to make the mouse In the inverted state, the mouse head was about 10 cm from the bottom, suspended for 6 minutes, and the cumulative time of the mice was recorded within 5 minutes after the recording.
  • the experimental data were expressed as ⁇ ffi», and the experimental results were analyzed by SPSS 11.5 statistical software for one-way analysis of variance.
  • Example 5 has a certain anti-realistic and depressive effect.
  • Example 5 was provided by O'Neill Bioengineering Technology Co., Ltd. (a pilot-scale product); Paroxetine was a product of Sino-US Tianjin Shike Pharmaceutical Co., Ltd. (batch number: 05070384), and the above drugs were formulated with physiological saline for intragastric administration.
  • mice male, weighing 20.0 ⁇ l g, secondary, provided by the Department of Experimental Animal Science, Peking University Medical School, Animal Quality Certificate No. SCXK (Beijing) 2006-0008.
  • mice were grouped and administered as a mouse tail suspension experiment. The mice in each group of the experiment were tested after 1 hour of administration. The mice were trained to swim for 15 minutes before the experiment and on the eighth day. After 24 hours, the mice were placed in a glass jar with a water depth of 10 cm and a diameter of 14 cm. The water temperature was 25 ⁇ , and the cumulative time of the mice in the water was recorded for 5 minutes.
  • the experimental data is represented by soil, and the experimental results were analyzed by SPSS 11.5 statistical software for one-way analysis of variance.
  • Example 5 has a certain antidepressant effect.
  • Example 2 After extracting Example 1 and Example 4, 9 kg of ginseng residue, 7 kg of licorice residue and 0.9 kg of jujube residue were collected, and dried, pulverized and mixed to obtain a very small amount of ginsenoside Rgl, Rbl, A control mixture of the effects of glycyrrhizic acid and jujube cAMP on the tail suspension test in mice.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Residue mixture Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • mice were randomly divided into groups of 10: 1. High-dose group of residue mixture (160 mg/kg, PO, 7d); 2. Dose group in the residue mixture (80 mg kg, PO, 7d); 3. Low-dose group of residue mixture (40 mg/kg, PO, 7d); 4. Paroxetine group (3 mg/kg, PO, 7d); 5. Normal saline group (PO).
  • a tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was suspended with a tape on the 5 cm-thickness of the head and suspended for 6 minutes, and the immobility time of the mouse within 5 minutes after the recording was recorded.
  • the high, medium and low dose groups of the residue mixture can shorten the immobility time after the tail of the mouse, but there is no significant difference compared with the saline group (model group), so it can be inferred.
  • This residue mixture does not have an anti-experimental depression function.
  • the oral drug for treating depression according to the present invention may contain a pharmaceutically acceptable additive
  • the oral drug for treating depression according to the present invention can be processed into various known dosage forms such as powders, capsules, tablets, and the like;
  • the oral medicament for treating depression according to the present invention can be formulated into a health food for treating depression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

多靶标受体后作用机制用于治疗忧郁症的药物组合物
技术领域
本发明涉及一组以包含人参皂甙 Rgl、 Rbl及甘草酸及大枣环磷酸腺苷 (大枣 cyclic adenosine monophosphate, 大枣 cAMP )的原料,制成多 巴标受 体后作用机制用于治疗忧郁症的药物, 尤其涉及一种功效成份明确、疗效明 显、长期服用安全性高、能避免引起强呕吐等副作用的治疗忧郁症的口服药 物或保健食品。 背景技术
忧郁症是一种常见的疾病, 据统计在一般人口中大约有 25%女性在其 一生中经历过忧郁症, 男性中约有 10%左右经历过忧郁症(张春兴著: 《现 代心理学》 )。 世界卫生组织 (WHO )提供的数据: 忧郁症在全世界的发 病率约为 11%, 目前全球约有 3.4亿精神忧郁患者, 而且这个数字仍成上升 趋势, 调查发现在今后 20年, 忧郁症将会上升为全球第二大常见疾病。
现有技术中, 抗忧郁药物以百忧解、 赛乐特、 左洛复等(SSRI、 SN I、 NDRI等类的 5-HT、 E、 DA再摄取抑制剂)为主, 其作用机制是通过增加 人体神经介质内 5羟色胺等成分含量以援解忧郁症状。
但是, 已问市的抗忧郁药物都有不同程度的副作用, 例如: 增加自杀 率、 头痛、 头晕、 晕眩、 失眠、 嗜睡、 耳鸣、 口干、 厌食、 食欲增加、 体重 上升、 血压上升、 肠胃不适、 反胃、 恶心、 呕吐、 消化不良、 腹泻、 便秘、 下肢痛、 皮肤出疹、 颤抖、 痉挛、 多汗、 水肿、 性欲降低、 性无能等。 近年 来百忧解等抗忧郁药物已成为社会严重关注的问题,美国食品暨药物管理局 ( Food and Drug Administration, FDA )更于 2004年要求药厂将市场上主要 的 32种抗忧郁药物重新标示其副作用和警告的部分, 并对医护人员强调这 些药物可能增加儿童及青少年自杀的机率。 其中, 赛乐特更是早在 1996年 就被发现存在有安全隐患, 自 2001年开始已陆续从市场上召回。 2004年 6 月, 美国纽约州总检察长指控英国葛兰素史克公司为了获取利润,欺骗性隐 瞒了服用赛乐特与"增加青少年自杀倾向及行为的风险 "之间有关联的研究 报告。在这种背景下,如何研发新一代副作用低叉能有明显抗忧郁作用的药 物已成为全球医药界所关注的问题。
近年来, 国际医药界的科学家们在忧郁症致病机理的研究方面出现了 新的突破, 发现除了以 5-HT、 NE、 DA的再摄取抑制方式治疗忧郁症之外, 更可以采取调节受体后作用机制的方式治疗忧郁症,并且由于受体后作用机 制调节类药物罗列普拉 ( Rolipram )的问世而成为医药界抗忧郁药物的研发 热点。 罗列普拉是四型磷酸二酯酶( phosphodiesterase 4, PDE4 )的抑制剂, 临床试验表明其具有明显的抗忧郁作用,但由于服用罗列普拉会出现强烈呕 吐, 故被迫终止研发, 然而罗列普拉却开拓了新一代 "受体后作用机制抗抑 郁药物" 的研发思路。
综上所述, 申请人在了解了公知技术中所具有的局限性后, 经过悉心研 究与探索, 并本着锲而不舍的精神, 终于发现了本发明的 "多靶标受体后作 用机制用于治疗抑郁症的药物组合物" , 以下为本发明的简要说明。 发明内容
为了克服现有技术的不足,本发明的目的在于提供一组以包含人参皂甙 Rgl、 Rbl、 甘草酸及大枣 cAMP的原料, 制成多靶标受体后作用机制用于 治疗抑郁症的口服药物或保健食品, 特别是功效成份明确、疗效明显、 长期 服用安全性高、 不会引起强烈呕吐等副作用的新技术方案。
本发明药物的解决方案是经发明人潜心研究探索的结果, 依据现代医 学治疗忧郁症的病理及药理学理论,特别是结合受体后作用机制抗忧郁药靶 标研究, 经过大量的动物实验证明: 人参皂甙含有腺苷酸环化酶( adenylate cyclase, AC )刺激腺苷, 并含有 cAMP磷酸二酯酶(CAPD ) 的抑制成份; 甘草酸(甘草次酸)是 cAMP磷酸二酯酶(CAPD )强抑制剂。 人参皂甙、 甘草酸(甘草次酸)二者配伍, 协同作用, 可以进一步提高 cAMP的利用度 和活性,而 cAMP的浓度和活性增强,则可增加去甲肾上腺素( norepinephrine, NE )等神经递质的合成与释放, 增强脑源性神经营养因子 (brain-derived neurotrophic factor, BDNF ) 的表达, 抑制下丘脑-垂体-肾上腺轴 ( hypothalamic-pituitary-adrenal axis, HPA轴) 的亢进和糖皮质激素的分泌, 从而达到显著的抗忧郁功能。 另外, 大枣 cAMP亦可以提高人体 cAMP的 表达,从而起到抗忧郁作用,将大枣中含量极微(约万分之一)的大枣 cAMP 提取并純化成含 1%大枣 cAMP的大枣提取物来进行抗试- 性抑郁作用动物 试验的结果显示, 具有明显的抗试验性抑郁功能,但仅通过常规的例如用水 加温提取而未进一步纯化提高其提取物大枣 cAMP浓度的大枣提取物 ,虽然 含有微量的大枣 cAMP却不具有明显的抗试验性抑郁功能,为了进一步增强 本发明的抗忧郁功效, 还可将大枣 cAMP、 人参皂甙和甘草酸三者配伍。 人 参、甘草、 大枣是几千年以来中医及食补药膳常用的药材和食品, 在千百年 的食用和临床使用过程中, 已充分证明人参、甘草、大枣三者配伍的安全性, 发明人研究及实验的结果证明这三种药材若仅以常规使用的煎煮方式提取 所得的提取物和目前用于治疗忧郁症的抗忧郁药物相比不具备显著的抗忧 郁疗效;但再采取例如上柱层析的纯化方式进一步提高提取物中所含的人参 皂甙 Rgl、 Rbl及大枣 cAMP等有效成份的浓度, 再加上甘草酸或甘草次酸 等原料制成用于治疗忧郁症的药物,经过动物试验证明和目前用于治疗忧郁 症的抗忧郁药物相比具有显著的抗忧郁功能;收集三种药材提取及上柱层析 纯化得到提取物后剩余的残渣, 以高效液相检测后虽然含微量的人参皂甙 Rgl、 R 、 甘草酸和大枣 eAMP, 但是经过动物试验后证明没有显著的抗 忧郁功能; 而服用人参、甘草及大枣不会发生强烈呕吐等副作用, 故发明人 提出以人参皂甙 Rgl、 Rbl及甘草酸和大枣 cAMP为原料, 制成多靶标受体 后作用机制用于治疗忧郁症的口服药物或保健食品, 特别是除了例如用水、 乙醇等溶剂加温提取之外更进一步纯化提高提取物中人参皂甙 Rgl、 Rbl及 大枣 cAMP浓度的原料加上含甘草酸或甘草次酸等原料制成功效成份明确、 疗效明显、长期服用安全性高、不会引起强烈呕吐等副作用的新技术方案以 改进公知技术中所具有的不足之处。
本发明药物组合物与罗列普拉抗忧郁的药物标的及作用机制比较
Figure imgf000005_0001
作用机制 1.启动 cAMP依赖的酪氨酸羟化酶, 1.启动 cAMP依赖的酪氨酸羟化酶, 增加 NE合成; 增加 E合成;
2.磷酸化突触蛋白, 增加 NE幹放; 2.磷酸化突触蛋白, 增加 NE释放;
3.抑制磷酸二酯酶, 减少 cAMP 降 3.抑制磷酸二酯酶,减少 cAMP降解 解,提高 cAMP利用度而发挥作用。 提高 cAMP利用度而发挥作用;
4.启动 AC, 增加 cAMP的浓度和活 性;
5.通过提高 ATP促使 cAMP的生成;
6.促进苯丙酸透过血脑屏障, 促进 NE、 DA的合成和下调 HPA轴;
7.通过直接上调脑细胞中 BDNF 和 NT-3的表达, 抗应' ¾ 应。
服药反应 会引起强烈呕吐等副作用。 长期服用安全性高、副作用低,且可 预防及改善神经退行性疾病及抗衰 老。
本发明药物与公知的受体后作用机制的抗忧郁药物罗列普拉不同之处, 在于既可以同样的通过多靶标受体后作用机制达到抗忧郁作用,又能避免如 服用罗列普拉后所引起的强烈呕吐等副作用。
由于甘草酸在人体内转化为甘草次酸的转化率几乎达到 100%, 而脂溶 性比甘草酸强的甘草次酸能够透过血脑屏障进入脑内,故甘草酸抑制 CAPD 起到抗忧郁功效是通过体内转化为甘草次酸来进行的, 因此,可以用甘草酸 或 草次酸为原料加工制成本发明的药物组合物。
本发明揭露了一种多耙标受体后作用机制用于治疗抑郁症的药物组合 物, 所述药物组合物是由包括人参皂甙 Rgl、 Rbl及甘草酸或甘草次酸的原 料所制成。
优选地,本发明的药物組合物,是由包括人参皂甙(Rgl+RM )合计 2〜26 重量份与甘草酸或甘草次酸 3~48重量份的原料所制成。
优选地,本发明的药物組合物,是由包括人参皂甙(Rgl+Rbl )合计 4〜13 重量份与甘草酸或甘草次酸 5〜16重量份的原料所制成。
根据本发明的另一概念,本发明揭露了一种多靶标受体后作用机制用于 治疗抑郁症的药物组合物, 所述药物组合物是由包括人参皂甙 Rgl、 Rbl及 甘草酸或甘草次酸及大枣 cAMP的原料所制成。 优选地,本发明的药物组合物 ,是由包括人参皂甙( Rgl+Rbl )合计 2〜26 重量份与甘草酸或甘草次酸 3〜48重量份及大枣 cAMP 0.002-0.5重量份的原 料所制成。
优选地, 本发明的药物组合物, 是由包括人参皂甙(Rgl+Rbl )合计 4-13重量份与甘草酸或甘草次酸 5~16重量份及大枣 cAMP 0.01-0.1重量份 的原料所制成。
优选地, 本发明的药物組合物可以包括药学上可接受的载体或添加剂, 可以制成锭剂、 胶嚢剂、 散剂、 片剂、 粉剂、 溶液剂、 微嚢剂、 混悬剂、 乳 剂、 颗粒剂、 滴丸剂、 丸剂等任何药剂学上所公知的口服药物剂型。
' 优选地,所述的药物组合物可用来制成用于治疗抑郁症的药物、保健食 品和营养剂。
本发明的说明书和权利要求中所述的用于治疗忧郁症的口服药物,是实 现本发明目的的核心内容,在本发明公开后, 本领域的技术人员可以根据中 医理论或是相关现代药理学理论,对上述药物进行常规的加减化裁或是用功 效作用相同的其它中药有效成分(如远志甙、柴胡甙、甘草香豆素等)替代。 这种常规的加减化裁和用作用机理相似或相同的其它 CAPD抑制剂、 AC启 动剂的中药或是相应的有效成分来替代,均属于本领域技术和研究人员的一 般性技术活动, 故其都在本发明的保护范围之内。
通过参阅附图及详细说明可以更好地了解本发明。 附图概述
图 1为制备本发明实施例 1药物的方法流程示意图。
图 2为制备本发明实施例 2药物的方法流程示意图。
图 3为制备本发明实施例 3药物的方法流程示意图。
图 4为制备本发明实施例 4药物的方法流程示意图。
图 5为制备本发明实施例 5药物的方法流程示意图。
图 6为制备本发明实施例 6药物的方法流程示意图。 本发明的较佳实施方式
以下将结合附图和实施例进一步说明本发明。本发明主要是采用本领域 技术人员公知的方法结合本发明的特征制备本发明所述的药物。以下实施例 仅仅是为了说明, 并非限定本发明。
为了完成本发明的目的, 本发明特别提出下列技术方案。
本发明揭露了一种多靶标受体后作用机制用于治疗抑郁症的药物組合 物, 所述药物組合物由包括人参皂甙 Rgl、 Rbl及甘草酸或甘草次酸的原料 制成。
方案一:
以含有人参皂甙 Rgl、 RM及甘草酸或甘草次酸的原料, 加工制成本发 明多靶标受体后作用机制用于治疗忧郁症的药物組合物。
方案二:
以含有人参皂甙( Rgl+Rbl )合计 2-26重量份与甘草酸或甘草次酸 3〜48 重量份的原料, 加工制成本发明的药物组合物。
方案三:
以含有人参皂甙(Rgl+Rbl )合计 4-13重量份与甘草酸或甘草次酸 5~16 重量份的原料, 加工制成本发明的药物组合物。
方案四:
以含有人参皂甙 Rgl、 Rbl、 甘草酸或甘草次酸及大枣 cAMP等原料, 加工制成本发明多靶标受体后作用机制用于治疗忧郁症的药物组合物。
方案五:
以含有人参皂甙(Rgl+Rbl )合计 2〜26重量份、甘草酸或甘草次酸 3〜48 重量份及大枣 cAMP 0.002~0.5重量份的原料, 加工制成本发明的药物组合 物。
方案六:
以含有人参皂甙(Rgl+Rbl )合计 4-13重量份、甘草酸或甘草次酸 5~16 重量份及大枣 cAMP 0.01-0.1重量份的原料,加工制成本发明的药物组合物。
方案七:
本发明的药物组合物可以包括药学上可接受的载体或添加剂,可以制成 锭剂、 胶嚢剂、 散剂、 片剂、 粉剂、 溶液剂、 微嚢剂、 混悬剂、 乳剂、 颗粒 剂、 滴丸剂、 丸剂等任何药剂学上所公知的口服药物剂型。
方案八:
本发明所述的药物组合物可用来制成用于治疗抑郁症的药物、保健食品 和营养剂。
为了完成本发明的目的, 特提出以下药物的制作方法。
方法一:
自人参及甘草中提取含有人参皂甙 Rgl、Rbl及甘草酸的提取物为原料, 或直接釆用已制备成的含有人参皂武 Rgl、Rbl及甘草酸或甘草次酸的原料, 加工制成本发明多靶标受体后作用机制用于治疗忧郁症的药物组合物。
方法二:
将含有人参皂甙( Rgl+Rbl )合计 2~26重量份与甘草酸或甘草次酸 3〜48 重量份的原料, 加工制成本发明的药物组合物。 方法三:
将含有人参皂甙( gl+Rbl )合计 4~13重量份与甘草酸或甘草次酸 5〜16 重量份的原料, 加工制成本发明的药物组合物。
方法四:
自人参及甘草及大枣中提取含有人参皂甙 Rgl、 Rbl、 甘草酸及大枣 cAMP的提取物为原料, 或直接采用已制备成的含有人参皂戒 Rgl、 Rbl、 甘草酸或甘草次酸及大枣 cAMP的原料,加工制成本发明多靶标受体后作用 机制用于治疗忧郁症的药物组合物。
方法五:
将含有人参皂甙( Rgl+Rbl )合计 2〜26重量份、甘草酸或甘草次酸 3~48 重量份及大枣 cAMP 0.002〜0.5重量份的原料, 加工制成本发明的药物组合 物。
方法六:
将含有人参皂甙( Rgl+Rbl )合计 4-13重量份、甘草酸或甘草次酸 5~16 重量份及大枣 cAMP 0.01-0.1重量份的原料,加工制成本发明的药物组合物。
方法七:
本发明所述的药物组合物可以包括药学上可接受的载体或添加剂,可以 制成锭剂、 胶嚢剂、 散剂、 片剂、 粉剂、 溶液剂、 微嚢剂、 混悬剂、 乳剂、 颗粒剂、 滴丸剂、 丸剂等任何药剂学上所公知的口服药物剂型。
方法八:
将本发明所述的原料依保健食品生产制造标准的方法,加工制成本发明 用于治疗忧郁症的保健食品。 具体实施例
以下将结合附图和具体实施例进一步说明本发明。
实施例 1
请参阅图 1, 其为制备本发明实施例 1药物的方法流程示意图。 在图 1 中, 先将 20 kg的人参破碎后用 70%乙醇溶液加温提取, 经上柱层析分离纯 化、 干燥, 得含 120 g人参皂甙(Rgl+Rbl ) 的人参提取物 0.8 kg; 接着, 再将 10 kg的甘草破碎后常温浸泡 12小时, 以水提醇沉法提取、 浓缩干燥, 得含甘草酸 200 g的甘草提取物 2 kg; 之后, 将上述方法得到的人参提取物 150 g及甘草提取物 200 g粉碎混合均匀后, 得 350 g (含 22.5 g人参皂甙 Rgl+Rbl及 20 g甘草酸)本发明方案一的药物組合物。
实施例 2
请参阅图 2, 其为制备本发明实施例 2药物的方法流程示意图。 在图 2 中,将已制备成纯度为 96%的甘草次酸 3.96 g及实施例 1所得的人参提取物 200 g粉碎混合均匀后, 得 203.96 g (含 30 g人参皂甙 Rgl+Rbl及 3.8 g甘 草次酸)本发明方案二的药物组合物。
实施例 3
请参阅图 3, 其为制备本发明实施例 3药物的方法流程示意图。 在图 3 中, 将已制备成的 3.4 g纯度为 90%的人参皂甙 Rgl、 7.8 g纯度为 90%的人 参鬼甙 Rbl及 36.8 g纯度为 95%的甘草酸粉碎混合均匀后,得 48 g (含 10 g 人参皂甙 Rgl+Rbl及 35 g甘草酸)本发明方案三的药物组合物。
实施例 4
请参阅图 4, 其为制备本发明实施例 4药物的方法流程示意图。 在图 4 中, 将 10 kg的大枣破碎后加水常温浸泡, 再以水提醇沉法提取获得大枣提 取液, 再用大孔树脂 OU-2、 ME-2两柱先后连续上柱吸附分离、 干燥, 得含 大枣 cAMP 0.3 g的大枣提取物 30 g作为原料供制备本发明药物。
接着, 将实施例 1得到的人参提取物 150 g、 甘草提取物 200 g及前述 大枣提取物 3 g粉碎混合均匀后, 得 353 g (含 22.5 g人参皂甙 Rgl+Rbl、 20 g甘草酸及 0.03 g大枣 cAMP )本发明方案四的药物组合物。
实施例 5
请参阅图 5, 其为制备本发明实施例 5药物的方法流程示意图。 在图 5 中 , 将实施例 1得到的人参提取物 150 g及甘草提取物 200 g及实施例 4得 到的大枣提取物 0.5 g粉碎混合均匀后, 得 350.5 g (含 22.5 g 人参皂甙 Rgl+ bK 20 g甘草酸及 0.005 g大枣 cAMP )本发明方案五的药物组合物。
实施例 6
请参阅图 6, 其为制备本发明实施例 6药物的方法流程示意图。 在图 6 中, 将已制备成的 6.8 g纯度为 90%的人参皂甙 Rgl、 15.6 g纯度为 90%的 人参皂甙 Rbl、 26 g纯度为 96%的甘草次酸及实施例 4得到的大枣提取物 10 g粉碎混合均匀后,得 58.4 g (含 20 g人参皂甙 Rgl+Rbl、 25 g甘草次酸 及 0.1 g大枣 cAMP )本发明方案六的药物组合物。
实验例一 实施例 1对小鼠悬尾实验的影响
1.1 实验动物
ICR小鼠, 雄性, 体重 22.0±2 g, 二级, 北京首都医科大学实验动物科 学部提供。
1.2 实验药品
实施例 1: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀(赛乐特) : 中美天津史克制药有限公司产品。
1.3 实验仪器: 秒表。 1.4剂量设计
实施例 1高剂量: 80 mg/kg/d,中剂量: 40 mg/kg/d及4氐剂量: 20 mg/kg/d。
1.5 实验方法及结果
1.5.1 分组给药
将小鼠随机分组, 每组 10只: 1.实施例 1高剂量組(80 mg/kg, PO, 给药 7d ); 2.实施例 1中剂量组(40 mg/kg, PO, 给药 7d ); 3.实施例 1低 剂量组(20 mg/kg, PO,给药 7d ); 4.帕罗西汀組( 3 mg/kg, PO,给药 7d ); 5.生理盐水组(PO )。 最后一次给药后 1小时进行悬尾实验。
1.5.2 实验方法
将小鼠尾(距尾尖 1 cm处)用胶布粘在头高出台面 5 cm的木条上悬吊
6分钟, 记录后 5分钟内小鼠的不动时间。
1.5.3 统计学处理
实验数据用 ±>¾)表示,实验结果用 SPSS 11.5统计软件进行方差分析。 1.5.4 实验结果
实验结果请参阅表 1。
表 1、 实施例 1对小鼠不动时间的影响
组 另'】 动物数(只) 不动时间 (秒) 生理盐水组(模型组) 10 113.22士 21.18 帕罗西汀組 10 75.33±22.91* 实施例 1高剂量组 10 54.67±26.38** 实施例 1中剂量組 10 72.68±27.06* 实施例 1低剂量组 10 95.26±49.91 注: 与模型组比较 * P<0.05 **P<0.01
结论:
根据以上实验, 可以看出本发明实施例 1高、 中剂量组和帕罗西汀组均 可減少小鼠悬尾后的不动时间, 且与生理盐水组(模型组)相比有显著性差 异, 从而可以推断本发明实施例 1具有抗实验性抑郁功能。
实验例 2 实施例 1对小鼠利血平诱导体温下降的影响
2.1 实验动物
ICR小鼠, 雄性, 体重 22.0±2 g, 二级, 北京首都医科大学实验动物科 学部提供。
2.2 实验药品
• 实施例 1: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀(赛乐特) : 中美天津史克制药有限公司产品。
利血平: 广东邦民制药厂有限公司。
2.3 实验仪器
GM222型电子温度计, 秒表。
2.4剂量设计
实施例 1高剂量: 80 mg/kg/d,中剂量: 40 mg kg/d及 4氐剂量: 20 mg/kg d。
2.5 实 ^方法及结果
2.5.1 分组给药
将小鼠随机分组, 每组 10只: 1.实施例 1高剂量组(80 mg/kg, PO, 给药 7d ); 2.实施例 1中剂量组(40 mg/kg, PO, 给药 7d ); 3.实施例 1低 剂量组(20 mg/kg, PO,给药 7d ); 4.帕罗西汀组( 3 mg/kg, PO,给药 7d ); 5.生理盐水组(PO ) 。
2.5.2 实险方法
在第 8天给药后 1小时测定小鼠肛温,然后经腹腔注射利血平 2 mg kg, 于注射利血平后 4小时再测定小鼠肛温。每次测温时温度计插入小鼠肛门的 深度及时间均一致。
2.5.3 统计学处理
实验数据用 ±5©表示,实验结果用 SPSS 11.5统计软件进行方差分析。 2.5.4 实验结果
. 实验结果请参阅表 2。
表 2、 实施例 1对小鼠利血平诱导体温下降的影响
组 另 动物数(只) 体温下降值(°c ) 生理盐水组(模型组) 10 3.65±0.77 帕罗西汀组 10 2.38±0.69** 实施例 1高剂量组 10 1.85±1.01** 实施例 1中剂量组 10 2.05±1.03** 实施例 1低剂量组 10 2.35±0.69** 注: 与模型组比较 *P<0.05 ** P<0.01
结论:
根据以上实验, 可以看出本发明实施例 1高、 中、低三个剂量组和帕罗 西汀组均可明显减少利血平诱导的体温下降,表明其抗实验性抑郁作用可能 与影响单胺递质含量有关,从而可以推断本发明实施例 1具有抗实^^性抑郁 功能。
实验例 3 实施例 1对小鼠悬尾实验的影响
3.1 实验动物
ICR小鼠, 雄性, 体重 22.0±2 g, 二级, 北京首都医科大学实 -险动物科 学部提供。
3.2 实验药品
实施例 2: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀(赛乐特): 中美天津史克制药有限公司产品。
3.3 实验仪器
秒表。
3.4剂量设计 实施例 2高剂量: 80 mg/kg/d,中剂量: 40 mg/kg/d及低剂量: 20 mg/kg/d。
3.5 实验方法及结果
3.5.1 分組给药
将小鼠随机分组, 每组 10只: 1.实施例 2高剂量组(80 mg/kg, PO, 给药 7d ); 2.实施例 2中剂量组(40 mg/kg, PO, 给药 7d ); 3.实施例 2低 剂量组( 20 mg/kg, PO,给药 7d ); 4.帕罗西汀组( 3 mg/kg, PO,给药 7d ); 5.生理盐氷组(PO ) 。 最后一次给药后 1小时进行悬尾实验。
3.5.2 实验方法
将小鼠尾(距尾尖 1 cm处)用胶布粘在头高出台面 5 cm的木条上悬吊 6分钟, 记录后 5分钟内小鼠的不动时间。
3.5.3 统计学处理
实验数据用 ± S£>表示,实验结果用 SPSS 11.5统计软件进行方差分析。
3.5.4 实验结果
实验结果请参阅表 3。
表 3、 实施例 2对小鼠不动时间的影响
组 别 动物数(只) 不动时间 (秒) 生理盐水组(模型组) 10 113.22士 21.18 帕罗西汀组 10 75.33±22.91* 实施例 2高剂量组 10 93.27±36.42
实施例 2中剂量组 10 76.21±28.36* 实施例 2低剂量组 10 107.79±32.56 注: 与模型组比较 *P<0.05 ** P<0.01
结论:
根据以上实验,可以看出本发明实施例 2中剂量组和帕罗西汀组均可减 少小鼠悬尾后的不动时间, 且与生理盐水组(模型组)相比有显著性差异, 从而可以推断本发明实施例 2具有抗实验性抑郁功能。 实验例 4 实施例 2对小鼠利血平诱导体温下降的影响
4.1 实验动物
ICR小鼠, 雄性, 体重 22.0±2 g, 二级, 北京首都医科大学实验动物科 学部提供。
4.2 实验药品
实施例 2: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀(赛乐特): 中美天津史克制药有限公司产品。
利血平: 广东邦民制药厂有限公司。
4.3 实验仪器
GM222型电子温度计, 秒表。
4.4剂量设计
实施例 2高剂量: 80 mg/kg/d.中剂量: 40 mg/kg/d及低剂量: 20 mg kg/d。
4.5 实睑方法及结果
4.5.1 分组给药
将小鼠随机分组, 每组 10只: 1,实施例 2高剂量组(80 mg kg, PO, 给药 7d ); 2.实施例 2中剂量组(40 mg/kg, PO, 给药 7d ); 3.实施例 2低 剂量组(20 mg/kg, PO,给药 7d ); 4.帕罗西汀组( 3 mg/kg, PO,给药 7d ); 5.生理盐水组(PO ) 。
4.5.2 实验方法
在第 8天给药后 1小时测定小鼠肛温,然后经腹腔注射利血平 2 mg/kg, 于注射利血平后 4小时再测定小鼠肛温。每次测温时温度计插入小鼠肛门的 深度及时间均一致。
4.5.3 统计学处理
实验数据用 ±5ΐ>表示,实验结果用 SPSS 11.5统计软件进行方差分析。 4.5.4 实验结果 实验结果请参阅表 4。
表 4、 实施例 2对小鼠利血平诱导体温下降的影响
组 别 动物数(只) 体温下降值( V ) 生理盐水组(模型组) 10 3.65±0.77 帕罗西汀组 10 2.38士 0.69** 实施例 2高剂量组 10 2.93±0.74* 实施例 2中剂量组 10 2.31±0.82** 实施例 2低剂量组 10 3.21士 0.71 注: 与模型组比较 * P<0.05 * <0.01
结论:
根据以上实验,可以看出本发明实施例 中剂量组和帕罗西汀组均可明 显减少利血平诱导的体温下降,表明其抗实验性抑郁作用可能与影响单胺递 盾含量有关, 从而可以推断本发明实施例 2具有抗实验性抑郁功能。
实验例 5 实施例 3对小鼠悬尾实验的影响
5.1 实-险动物
ICR小鼠, 雄性, 体重 22.0±2 g, 二级, 北京首都医科大学实验动物科 学部提供。
5.2 实验药品
实施例 3: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀(赛乐特): 中美天津史克制药有限公司产品。
5.3 实验仪器:
秒表。
5.4剂量设计
实施例 3高剂量: 80 mg kg/d、中剂量: 40 mg/kg/d及低剂量: 20 mg kg/d。
5.5 实验方法及结果 5.5.1 分组给药
将小鼠随机分组, 每組 10只: 1.实施例 3高剂量組(80 mg/kg, PO, 给药 7d ); 2.实施例 3中剂量组(40 mg/kg, PO, 给药 7d ); 3.实施例 3低 剂量组(20 mg/kg, PO,给药 7d ); 4.帕罗西汀组( 3 mg/kg, PO,给药 7d ); 5.生理盐水组(PO ) 。 最后一次给药后 1小时进行悬尾实验。
5.5.2 实验方法
将小鼠尾(距尾尖 1 cm处)用胶布粘在头高出台面 5 cm的木条上悬吊 6分钟 , 记录后 5分钟内小鼠的不动时间。
5.5.3 统计学处理
实验数据用 土 表示,实验结果用 SPSS 11.5统计软件进行方差分析。 5.5.4 实臉结果
实验结果请参阅表 5。
表 5、 实施例 3对小鼠不动时间的影响
组 另 J 动物数(只) 不动时间 (秒) 生理盐水组(模型组) 10 113.22±21.18 帕罗西汀组 10 75.33±22.91* 实施例 3高剂量组 10 70.37±28.14* 实施例 3中剂量组 10 76.26±23.81* 实施例 3低剂量组 10 . 90.40士 31.32 注: 与模型组比较 *P<0.05 ** P<0.01
结论:
根据以上实验, 可以看出本发明实施例 3高、 中剂量组和帕罗西汀组均 可减少小鼠悬尾后的不动时间, 且与生理盐水组(模型组)相比有显著性差 异, 从而可以推断本发明实施例 3具有抗实验性抑郁功能。
实验例 6 实施例 3对小鼠利血平诱导体温下降的影响 6.1 实验动物
ICR小鼠, 雄性, 体重 22.0±2 g, 二级, 北京首都医科大学实验动物科 学部提供。
6.2 实验药品
实施例 3: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀(赛乐特): 中美天津史克制药有限公司产品。
利血平: 广东邦民制药厂有限公司。
6.3 实驗仪器
GM222型电子温度计, 秒表。
6.4剂量设计
实施例 3高剂量: 80 mg/kg/d,中剂量: 40 mg/kg/d及低剂量: 20 mg/kg/d。
6.5 实验方法及结果
6.5.1 分组给药
将小鼠随机分组, 每组 10只: 1,实施例 3高剂量组(80 mg/kg, PO, 给药 7d ); 2.实施例 3中剂量组(40 mg/kg, PO, 给药 7d ); 3·实施例 3低 剂量组(20 mg/kg, PO,给药 7d ) ; 4.帕罗西汀组( 3 mg/kg, PO, 给药 7d ) ; 5.生理盐水组(PO ) 。
6.5.2 实-险方法
在第 8天给药后 1小时测定小鼠肛温,然后经腹腔注射利血平 2 mg/kg, 于注射利血平后 4小时再测定小鼠肛温。每次测温时温度计插入小鼠肛门的 深度及时间均一致。
6.5.3 统计学处理
• 实验数据用 ±S£)表示,实-睑结果用 SPSS 11.5统计软件进行方差分析。 6.5.4 实验结果
实验结果请参阅表 6。
表 6、 实施例 3对小鼠利血平诱导体温下降的影响 組 别 动物数(只) 体温下降值( V ) 生理盐水组(模型组) 10 3.65士 0.77 帕罗西汀组 10 2.38±0.69** 实施例 3高剂量组 10 2.18士 0.92** 实施例 3中剂量组 10 2.36士 0.83** 实施例 3低剂量组 10 2.97土 0.67* 注: 与模型组比较 * P<0.05 **P<0.01
结论:
才艮据以上实验, 可以看出本发明实施例 3高、 中、低剂量组和帕罗西汀 组均可明显减少利血平诱导的体温下降,表明其抗实验性抑郁作用可能与影 响单胺递质含量有关, 从而可以推断本发明实施例 3 具有抗实验性抑郁功 f¾。
实验例 7 实施例 4对大鼠嗅球损毁实验的影响
7.1 实睑动物
嗅球毁损模型: 健康 Wistar雄性大鼠, 二级, 体重 330土20 g, 购于北 京维通利华实验动物技术有限公司 (合格证编号 SCXK (京) 2002-0003 ) 。
7.2试剂与药品
实施例 4由欧纳尔生物工程技术有限公司提供(批号: 060313 ), 帕罗 西汀为中美天津史克制药有限公司产品(批号: 0405001 1 ) , 以上药物用 0.5%羧甲基纤维素纳(CMC-Na )配制后供灌胃使用; 注射用青霉素钠为华 北制药股份有限公司产品(批号: S051 1204 ) ; 去曱肾上腺素 ( NE )及 5- 羟色胺(5-HT )标准品为 Sigma公司产品; 其它试剂均为市售。
7.3仪器
自制开野实验箱, 避暗实验箱, 大鼠脑立体定位仪, 高效液相色语仪, DFM-96型 10管放射免疫 γ计数器。 7.4 实验方法
7.4.1动物分组与给药方法
大鼠随机分 6组, 假手术组、 模型对照組、 实施例 4 高剂量组(60 mg/kg/d )、实施例 4中剂量组( 30 mg/kg/d )、实施例 4低剂量组( 15 mg/kg d )、 帕罗西汀组( 2 mg/kg d )。受试药与阳性药用 0.5%羧甲基纤维素纳( CMC-Na ) 配制。 每天一次灌胃给药。
7.4.2模型制备方法
大鼠用水合氯醛麻醉,麻醉后从大鼠前 门前 1 cm至前囱后 1 cm正中 线处切开, 暴露颅骨。 在距离前囱前 8 mm、 正中线两侧 2 mm处分另 l]开骨 窗, 直径约 2 mm。 用特制电烙铁垂直插入颅内 2秒, 破坏嗅球, 用止血海 棉填充骨窗缝合皮肤; 术后每 4天以腹腔注射(intraperitoneal, IP )给与青 霉素钠 40,000单位/ Kg, 并连续给与受试药物 24天。
7.5观测指标
7.5.1开野实验
开野实验箱由浅蓝色胶合板及铝合金框架构成( 1 m X 1 m X 0.4 m ) , 箱底划分为 25个方格(每个 20 cm x 20 cm ) , 沿四壁为外周格, 其余为中 央格。 将动物放入正中方格中, 观察 3分钟内动物的跨格次数(三爪以上跨 入邻格)和站立次数(两前肢离地 1 cm以上) 。
7.5.2被动回避实验一避暗法
· 实^:箱内由明、 暗两室组成, 中间有一个通道供大鼠出入, 暗室隔栅与 电击仪相联, 两室间有一活动隔板。 如大鼠进入暗室则遭电击。 训练时, 将 大鼠头背向洞口放入明室中适应 5分钟, 然后将隔板抽出观察 5分钟,记录 大鼠首次进入暗室时间 (触电潜伏期) , 此为学习成绩。 24 小时后重复测 试,抽出隔板并通电 5分钟观察大鼠第一次钻入暗室的时间,此为记忆成绩。
7.6统计学处理
实验数据用 iS 表示,实验结果用 SPSS 11.5统计软件进行方差分析。
7.7 实-睑结果 7.7.1 开野实验结果请参阅表 7。
表 7、 嗅球毁损模型大鼠开野实验结果
水平运动 垂直运动 动物数
(跨格次数) (直立次数) 实施例 4高剂量组 11只 49.18 + 27.68 ** 10.91 ±6.91 ** 实施例 4中剂量组 11只 54.55 ±23.01 13.45 ±5.72* 实施例 4低剂量组 11只 61.82 ±21.43 15.18 ±4.47 帕罗西汀组 11只 55.36 ±25.96* 14.36 ±5.55 模型组 11只 79.55 ± 24.33 19.09土 8.53 假手术组 11只 45.36 ±26.84** 10.45 ±6.19 ** 注: 与模型组比较 *P<0.05 ** P<0.01
7.7.2避暗实验结果请参阅表 8。
表 8、 嗅球毁损模型大鼠避暗实验结果
动物数 第一天潜伏期 (S) 第二天潜伏期 (S) 实施例 4高剂量组 11只 187.00 ±87.59* 289.82 ±28.59 * 实施例 4中剂量组 11只 191.71 +72.95 * 288.82 + 37.09* 实施例 4低剂量组 11只 152.44 + 76.81 271.18 ±38.61 帕罗西汀组 11只 181.87 ±90.54* 265.00土 65.39 模型组 11只 111.21 + 82.93 236.88 + 74.17 假手术组 11只 211.46± 82.10** 292.82 ± 14.37 * 注: 与模型组比较 *P<0.05 ** P<0.01
结论:
实验例 7结果显示: 实施例 4高剂量组可明显改善嗅球毁损所造成的大 鼠水平及垂直运动增加,实施例 4中剂量组对嗅球毁损模型大鼠的垂直运动 增加也有明显改善作用。 另外, 实施例 4高、 中剂量组对嗅球毁损所造成的 大鼠学习及记忆功能减退也有明显改善作用。
实验例 8 实施例 4对大鼠不可预测长期应激实验的影响
8.1 实验
不可预测性长期应激模型:健康 Wistar雄性大鼠,二级,体重 240 ~ 270 g, 购于北京维通利华实验动物技术有限公司 (合格证编号 SCXK (京) 2002-0003 ) 。
8.2试剂与药品
实施例 4由欧纳尔生物工程技术有限公司提供(批号: 060313 ) , 帕罗 西汀为中美天津史克制药有限公司产品(批号: 04050011 ) , 以上药物用 0.5%羧曱基纤维素纳(CMC-Na )配制后供灌胃使用; 注射用青霉素钠为华 北制药股份有限公司产品(批号: S0511204 ); 去甲肾上腺素(NE )及 5- 羟色胺(5-HT )标准品为 Sigma公司产品; 其它试剂均为市售。
8.3仪器
自制开野实验箱, 避暗实验箱, 大鼠脑立体定位仪, 高效液相色语仪,
DFM-96型 10管放射免疫 γ计数器。
8.4 实验方法
8.4.1 动物分组与给药方法
大鼠随机分 6组, 假手术组、 模型对照组、 实施例 4 高剂量组(60 mg/kg/d )、实施例 4中剂量組( 30 mg/kg/d )、实施例 4低剂量组( 15 mg kg/d )> 帕罗西汀组 ( 2 mg/kg/d )。受试药与阳性药用 0.5%羧曱基纤维素纳( CMC-Na ) 配制。 每天一次灌胃给药。
8.4.2模型制备方法
不可预测性长期应激模型: 空白对照组正常饮食饮水, 不给任何刺激。 其它五组, 每笼饲养 1只, 并接受 24天不可预知的应激刺激, 包括: 3次 24小时禁食, 3次 24小时断水, 3次 24小时潮湿垫料(鼠盒中加水 200 ml ), 3次通宵照明, 3次 4°C冷水游泳 5分钟, 3次 45°C烤箱热烘 5分钟, 3次 1 分钟夹尾, 及 3次 30分钟高速水平振荡。 每天随机给予一种刺激, 共刺激 24天, 每种刺激不得连续给予。 每天一次灌胃给药, 共 24天。
8.5观测指标
8.5.1 开野实 同上。
8.5.2被动回避实—除: 同上。
8.5.3大鼠强迫游泳
末次给药后实验分两天进行。 第一天预试 15分钟, 玻璃缸内装 25°C温 水, 水深 25 cm。 24小时后, 进行正式实验, 给药后 1小时, 将大鼠放入叙 中, 观察并记录 5分钟不动时间。
8.5.4体重测试
- 比较各组动物实 前后体重的增加值。
8.5.5饮蔗糖水量测试:
比较各种动物蔗糖摄入量。 让各组大鼠饮用 1%的蔗糖水(定时为 1小 时) , 应激前、 应激后 3周各测一次饮水量; 大鼠在禁食禁水 14小时后, 将 1%的蔗糖水放入笼中代替原来的饮用水。 称量记录大鼠饮用蔗糖水 1小 时前后的瓶重的差值计算每次的蔗糖水饮用量。比较各组每一次测试中糖水 摄入量的差异。
8.5.6高效液相一电化学检测法
测定大鼠大脑皮质中 NE及 5-HT含量。
8.6统计学处理
实验数据用 ^土 表示,实验结果用 SPSS 11.5统计软件进行方差分析。 8.7 实验结果
8.7.1 大鼠饮蔗糖水量结果请参阅表 9。
表 9、 不可预测性长期应激模型大鼠饮蔗糖水量
动物数 饮蔗糖水量 (g) 实施例 4高剂量组 13只 22.55士 5.03 实施例 4中剂量组 13只 26.53 ±4.99 **
.实施例 4低剂量组 13只 26.97士 6.93 ** 帕罗西汀组 13只 26.29 ±4.87 ** 模型组 13只 19.42 ±4.25 空白对照组 13只 29.41 +3.83 ** 注: 与模型组比较 *P<0.05 **P<0.01
2 大鼠体重增量结果请参阅表 10。
表 10、 不可预测性长期应激模型大鼠体重增量
动物数 体重增量 (g) 实施例 4高剂量组 13只 86.08 ± 10.84 实施例 4中剂量组 13只 96.00 ± 11.05 ** 实施例 4低剂量组 13只 95.15 ±15.46 ** 帕罗西汀组 13只 96.85 ±9.30** 模型组 13只 84.92 ± 12.61 空白对照组 13只 120.54 ± 10.60 ** 注: 与模型组比较 **P<0.01
3大鼠强迫游泳实-睑不动时间结果请参阅表 11。
表 11、 不可预测性长期应激模型大鼠强迫游泳实验不动时间 动物数 不动时间 (秒) 实施例 4高剂量组 13只 23.28 ± 18.05 ** 实施例 4中剂量組 13只 18.95 ± 12.55 ** 实施例 4低剂量组 13只 25.20 ± 13.60* 帕罗西汀组 13只 31.38 + 19.59 模型组 13只 39.95 ± 17.46 空白对照组 13只 26.96士 12.76 * 注: 与模型组比较 <0.05, ** P<0.01
.7.4大鼠开野实验结果请参阅表 12。
不可预测性长期应邀模型大鼠开野实验结果
垂直运动 (直立次 动物数 水平运动(跨格次数)
数) 实施例 4高剂量组 14 58.31 士 15.35 * 16.54 ± 4.24 ** 实施例 4中剂量组 14 49.15 ± 14.26 13.54 ± 4.48 实施例 4低剂量组 14 52.62 + 21.83 16.15 ± 7.32 * 帕罗西汀组 14 61.85 ± 21.68 ** 14.69 + 4.2 模型组 14 39.54 ± 16.31 11.46 + 3.26 空白对照组 14 64.00 ± 11.97 ** 16.85 ± 3.18 ** 注: 与模型组比较 *P<0.05, ** P<0.01
.7.5大鼠避暗实验结果请参阅表 13。
表 13、 不可预测性长期应激模型大鼠避暗实验结果
动物数 第一天潜伏期 (S) 第二天潜伏期 (S) 实施例 4 高剂量 13只 65.43 ± 31.44 259.22 ± 56.51 組 13只 58.18 ± 18.0 212.76 ± 77.27 实施例 4 中剂量 13只 75.98 ± 32.22 * 204.85 ± 94.99 组
13只 75.75 + 46.52 * 257.46 ± 66.92 实施例 4 低剂量
13只 50.01 ± 15.7 189.25 ± 111.99
13只 80.00 ± 39.17 * 263.38 ± 59.68 帕罗西汀組
模型组
空白对照组
注: 与模型组比较 *P<0.05 ** P<0.01
.7.6 大鼠大脑皮质中 NE及 5- HT含量检测结果请参阅表 14。 表 14、 不可预测性长期应激模型大鼠大脑皮质中 E及 5-HT含量 动物
5-HT E
Mi-
(nmol/L脑组织匀浆) (nmol/L脑组织匀浆)
(只)
实施例 4高剂量组 12 230.4157±47.78554* 269.5409±58.86389** 实施例 4中剂量组 12 303.4418±70.31711** 227.2976士 28.95101** 实施例 4低剂量组 12 332.7343±76.25168** 201.8688±29.80775** 帕罗西汀组 12 227.0637±46.53838* 220.5419±38.31681** 模型组 12 179.3866±20.49374 57.6671±77.66958 空白对照组 12 228.1478±28.40397* 132.8598±20.84756** 与模型组比较 *P<0.05 ** P<0.01
结论:
实 -捡例 8结果显示:实施例 4中小剂量组可明显改善不可预测性长期应 激刺激所造成的饮蔗糖水量减少及体重下降;实施例 4高中低剂量组均可明 显增加大鼠强迫游泳实验不动时间;实施例 4高剂量组可明显改善不可预测 性长期应激刺激所造成的大鼠水平及垂直运动减少,实施例 4低剂量组对不 可预测性长期应激刺激所造成的大鼠垂直运动减少也有明显改善作用;实施 例 4 剂量组对不可预测性长期应激刺激所造成的大鼠学习能力降低有改 善作用; 实施例 4高中低剂量组均可明显增加大鼠大脑皮质中 E及 5-HT 含量。
实验例 9 实施例 5对小鼠悬尾实-睑的影响
9.1 药品
实施例 5由欧纳尔生物工程技术有限公司提供(中试放大产品); 帕罗 西汀为中美天津史克制药有限公司产品(批号: 05070384 ) , 以上药物用生 理盐水配制后供灌胃使用。
9.2动物 ICR小鼠, 雄性, 体重 20.0±l g, 二级, 由北京大学医学部实 -险动物科 学部提供, 动物质量合格证号 SCXK (京) 2006-0008。
9.3仪器
秒表。
9.4方法
小鼠 70只, 随机平均分成 5组, NS组、 帕罗西汀组(3 mg/kg/d )、 实 施例 5高剂量组(80 mg/kg/d )、 实施例 5中剂量组(40 mg/kg/d )、 实施例 5低剂量组(20 mg/kg/d ) 。 每日灌胃给药一次, 于第八天给药后 1小时将 小鼠尾端 (距尾尖 1 cm处)用胶布粘在置于一敞口箱内的水平支撑物上, 使小鼠呈倒悬状态, 小鼠头距底面约 10 cm, 悬吊 6分钟, 记录后 5分钟内 小鼠的累积不动时间。
9.5统计学处理
实验数据以 ±ffi»表示, 实验结果用 SPSS 11.5统计软件进行单因素方 差分析。
9.6结果
小鼠悬尾实验不动时间结果请参阅表 15。
表 15、 实施例 5对小鼠悬尾实验累积不动时间的影响
动物数 (只) 剂量 (mg/kg/d) 不动时间 (秒) 实施例 5高剂量组 14 80 64.75±42.22** 实施例 5中剂量组 14 40 55.41±33.83** 实施例 5低剂量组 14 20 62.75±26.61** 帕罗西汀组 14 3 53.27±20.02**
NS组 14 113.59±36.11 注: 与 NS组比较 *P<0.05 ** P<0.01
结论:
研究结果显示实施例 5高、 中、低三个剂量组及临床有效的抗抑郁药帕 罗西汀均可明显缩短小鼠悬尾累积不动时间,表明实施例 5具有一定的抗实 一险性抑郁作用。
实 ^瞼例 10 实施例 5对小鼠强迫游泳实 3 的影响
10.1 药品
实施例 5由欧纳尔生物工程技术有限公司提供 (中试放大产品); 帕罗 西汀为中美天津史克制药有限公司产品(批号: 05070384 ) , 以上药物用生 理盐水配制后供灌胃使用。
10.2动物
ICR小鼠, 雄性, 体重 20.0±l g, 二级, 由北京大学医学部实验动物科 学部提供, 动物质量合格证号 SCXK (京) 2006-0008。
10.3 仪器
秒表。
10.4 方法
小鼠分组及给药如同小鼠悬尾实验。实验各组小鼠于给药 1小时后进行 实验, 实验前及第八天小鼠训练游泳 15分钟, 24小时后测试, 将小鼠分别 放入水深 10 cm、 直径 14 cm的玻璃缸中, 水温 25Ό , 观察 5分钟记录小鼠 在水中的累积不动时间。
10.5 统计学处理
实验数据以 土 表示, 实验结果用 SPSS 11.5统计软件进行单因素方 差分析。
10.6 结果
小鼠强迫游泳实验结果请参阅表 16。
表 16、 实施例 5对小鼠强迫游泳实验的影响
动物数 剂量 (mg/kg/d) 不动时间 (秒) (只) 实施例 5高剂量组 14 80 88.35±51.64* 实施例 5中剂量组 14 40 65.87±38.96** 实施例 5低剂量组 14 20 88.12±38.57* 帕罗西汀组 14 3 57廉 38.07**
■ NS组 14 132.47±40.64 注: 与 NS组比较 <0.05 ** P<0.01
结论:
研究结果显示实施例 5高、 中、低剂量组及临床有效的抗抑郁药帕罗西 汀均可明显缩短小鼠强迫游泳累积不动时间,表明实施例 5具有一定的抗实 验性抑郁作用。
实验例 11
将实施例 1及实施例 4提取后收集所剩的人参残渣 9公斤、 甘草残渣 7 公斤与大枣残渣 0.9公斤, 将其干燥、 粉碎、 混合均匀后得含极微量的人参 皂甙 Rgl、 Rbl、 及甘草酸和大枣 cAMP的残渣混合物, 进行对小鼠悬尾实 验的影响的对照试验。
11.1 实 ^验动物
ICR小鼠, 雄性, 体重 22.0±2 g, 二级, 北京首都医科大学实验动物科 学部提供。
11.2 实验药品
残渣混合物: 北京欧纳尔生物工程技术有限公司提供。
帕罗西汀(赛乐特) : 中美天津史克制药有限公司产品。
11.3 实验仪器
秒表。
11.4剂量设计
• 残渣混合物高剂量: 160 mg kg d、 中剂量: 80 mg kg/d及、 低剂量: 40 mg/kg/d0
11.5 实猃方法及结果
11.5.1 分组给药
将小鼠随机分组,每組 10只: 1.残渣混合物高剂量组( 160 mg/kg, PO, 给药 7d ); 2.残渣混合物中剂量组(80 mg kg, PO, 给药 7d ); 3.残渣混合 物低剂量组(40 mg/kg, PO, 给药 7d ); 4.帕罗西汀组(3 mg/kg, PO, 给 药 7d ); 5.生理盐水组(PO )。 最后一次给药后 1小时进行悬尾实验。
11.5.2 实验方法
将小鼠尾(距尾尖 1 cm处)用胶布粘在头高出台面 5 cm的木奈上悬吊 6分钟, 记录后 5分钟内小鼠的不动时间。
11.5.3 统计学处理
实验数据用 ±5 )表示,实验结果用 SPSS 11.5统计软件进行方差分析。 11.5.4 实验结果
实验结杲请参阅表 17。
表 17、 残渣混合物对小鼠不动时间的影响
动物数(只) 不动时间 (秒) 生理盐水组(模型组) 10 82.03±43.01 帕罗西汀组 10 38.37±20.76* 残渣混合物高剂量组 10 76.91士 31.09 残渣混合物中剂量组 10 78.89±48.18 残渣混合物低剂量组 10 81.31±58.68
注: 与模型组比较 * P<0.05 **P<0.01
结论:
根据以上实验, 可以看出残渣混合物高、 中、 低三个剂量组虽可缩短小 鼠悬尾后的不动时间, 但与生理盐水組(模型组)相比差异无显著性, 从而 可以推断该残渣混合物不具有抗实验性抑郁功能。 本发明用于治疗忧郁症的口服药物的应用范围:
1. 本发明所述的用于治疗忧郁症的口服药物中, 可以含有药物学上可 接受的添加剂;
' 2.本发明所述的用于治疗忧郁症的口服药物可以将其加工制成散剂、 胶嚢剂、 片剂、 等各种已知的剂型; 以及
3. 本发明所述的用于治疗忧郁症的口服药物可以制成用于治疗忧郁症 的保健食品。
本领域技术人员可以对本发明做出各种改进,而不脱离如所附权利要求 的保护范围。

Claims

权 利 要 求 书
1. 一种多靶标受体后作用机制用于治疗忧郁症的药物组合物, 包括: 人参皂甙, 其包含 Rgl及 Rbl; 及
甘草酸类, 其由选自含甘草酸、 甘草次酸及其组合之一的原料制成。
2. 如权利要求 1 所述的药物组合物, 其中所述药物组合物包括 2 ~ 26 重量份的所述人参皂甙 Rgl + RW及 3〜48重量份的所述甘草酸类。
3. 如权利要求 1 所述的药物组合物, 其中所述药物组合物包括 4 ~ 13 重量份的所述人参皂甙 Rgl + Rbl及 5 ~ 16重量份的所述甘草酸类。
4. 如权利要求 1 所述的药物組合物, 其中所述药物组合物包括的所述 人参皂甙是舍人参皂甙 Rgl及 Rbl的人参提取物; 所迷甘草酸类是含甘草 酸的甘草提取物。
5. 如权利要求 1 所述的药物组合物, 其中所述药物组合物含有选自药 学上可接受的载体、 添加剂及其组合之一。
6. 如权利要求 1 所述的药物組合物, 其中所述药物组合物制成剂型, 所述剂型选自锭剂、胶嚢剂、散剂、 片剂、 粉剂、溶液剂、微嚢剂、 混悬剂、 乳剂、 颗粒剂、 滴丸剂、 丸剂及药剂学上的口服药物剂型之一。
7. 如权利要求 1 所述的药物組合物, 其中所述药物组合物制成保健食 品或营养剂。
8. 一种多靶标受体后作用机制用于治疗忧郁症的药物组合物, 包括: 人参皂甙, 其包含 Rgl及 Rbl;
甘草酸类, 其选自甘草酸、 甘草次酸及其组合之一; 及
大枣环磷酸腺苷为原料制成。
9. 如权利要求 8 所述的药物组合物, 其中所述药物组合物包括 2 ~ 26 重量份的所述人参皂甙 Rgl + Rbl、 3 ~ 48重量份的所迷甘草酸类及 0.002 ~
0.5重量份的所述大枣环磷酸腺苷。
10.如权利要求 8所述的药物組合物, 其中所述药物组合物包括 4 ~ 13 重量份的所述人参皂甙 Rgl + Rbl、 5 - 16重量份的所述甘草酸类及 0.01 ~ 0.1重量份的所述大枣环磷酸腺苷。
11.如权利要求 8所迷的药物组合物, 其中所述药物组合物包括的所述 人参皂甙是含人参皂甙 Rgl及 Rbl的人参提取物; 所述甘草酸类是含甘草 酸的甘草提取物; 所述大枣环磷酸腺苷是含大枣环磷酸腺苷的大枣提取物。
12. 如权利要求 8所述的药物组合物, 其中所述含大枣环磷酸腺苷的原 料是下述的第二提取物: 先提取大枣获得第一提取物,再纯化所述第一提取 物得所述第二提取物,其中所述第二提取物的大枣环磷酸腺苷浓度高于所述 第一提取物的大枣环磷酸腺苷浓度。
13. 如权利要求 8所述的药物组合物, 其中所述药物组合物含有选自药 学上可接受的载体、 添加剂及其组合之一。
14.如权利要求 8所述的药物組合物, 其中所述药物组合物制成剂型, 所述剂型选自锭剂、胶嚢剂、散剂、 片剂、粉剂、溶液剂、微嚢剂、 混悬剂、 乳剂、 颗粒剂、 滴丸剂、 丸剂及药剂学上的口服药物剂型之一。
15. 如权利要求 8所述的药物组合物, 其中所述药物组合物制成保健食 品或营养剂。
16. 一种多靶标受体后作用机制用于治疗忧郁症的药物组合物的含大 枣环磷酸腺苷的原料的制备方法, 其包括下列步骤:
(a)提取大枣获得第一提取物; 及
(b) 纯化所述第一提取物获得第二提取物,
其中所述第二提取物的大枣环磷酸腺苷浓度高于所述第一提取物的大 枣环磷酸腺苷浓度。
.
17.如权利要求 16所述的制备方法,其中步驟 (b)选用含酪基的大孔树脂 上柱吸附分离所述第一提取物中的大枣环磷酸腺苷。
18.如权利要求 17所述的制备方法,其中步驟 (b)选用含 基的大孔树脂
OU-2上柱吸附分离所述第一提取物中的大枣环磷酸腺苷。
19.如权利要求 18所述的制备方法, 其中步骤 (b)再以大孔树脂 ME-2上 柱分离所述第一提取物中的大枣环磷酸腺苷。
PCT/CN2007/003400 2007-11-30 2007-11-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression WO2009070924A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP07845763A EP2216040A4 (en) 2007-11-30 2007-11-30 PHARMACEUTICAL COMPOSITIONS WITH MULTI-TARGET RECEIVER FEEDBACK MECHANISM FOR THE TREATMENT OF DEPRESSION
KR1020107012032A KR20100091206A (ko) 2007-11-30 2007-11-30 우울증 치료를 위한 다중 표적 리셉터 레트로액션 매커니즘을 갖는 제약 조성물
PCT/CN2007/003400 WO2009070924A1 (en) 2007-11-30 2007-11-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
US12/745,459 US20100311674A1 (en) 2007-11-30 2007-11-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
BRPI0722182-7A BRPI0722182A2 (pt) 2007-11-30 2007-11-30 "compostos farmacêuticos com um mecanismo de retroação multi-alvo receptor para o tratamento da depressão"
MX2010005840A MX2010005840A (es) 2007-11-30 2007-11-30 Composiciones farmaceuticas con un mecanismo de retroaccion de receptor multi-objetivo para tratar la depresion.
CA2746663A CA2746663A1 (en) 2007-11-30 2007-11-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
JP2010535193A JP5628682B2 (ja) 2007-11-30 2007-11-30 鬱病治療のための薬剤組成物
AU2007361992A AU2007361992B2 (en) 2007-11-30 2007-11-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
IL206082A IL206082A0 (en) 2007-11-30 2010-05-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
ZA2010/04033A ZA201004033B (en) 2007-11-30 2010-06-04 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003400 WO2009070924A1 (en) 2007-11-30 2007-11-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression

Publications (1)

Publication Number Publication Date
WO2009070924A1 true WO2009070924A1 (en) 2009-06-11

Family

ID=40717257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/003400 WO2009070924A1 (en) 2007-11-30 2007-11-30 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression

Country Status (11)

Country Link
US (1) US20100311674A1 (zh)
EP (1) EP2216040A4 (zh)
JP (1) JP5628682B2 (zh)
KR (1) KR20100091206A (zh)
AU (1) AU2007361992B2 (zh)
BR (1) BRPI0722182A2 (zh)
CA (1) CA2746663A1 (zh)
IL (1) IL206082A0 (zh)
MX (1) MX2010005840A (zh)
WO (1) WO2009070924A1 (zh)
ZA (1) ZA201004033B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533535A (ja) * 2009-07-16 2012-12-27 シージェイ チェイルジェダン コーポレーション ジンセノサイド濃縮画分を含む血圧降下用組成物
AU2016256704B2 (en) * 2012-08-15 2018-08-02 Chi, Yu Fen Pharmaceutical composition increasing cyclic AMP content and availability in vivo, and preparation method thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100509006C (zh) 2005-03-25 2009-07-08 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法
KR20130002292A (ko) * 2011-06-28 2013-01-07 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
CN103655778A (zh) * 2013-12-16 2014-03-26 无锡济民可信山禾药业股份有限公司 一种治疗急性戒毒综合症药物新的制剂及其制备方法
CN107254503B (zh) * 2017-08-04 2021-04-09 齐鲁工业大学 一种人参皂苷Rd的酶催化转化制备方法
CN110193019B (zh) * 2019-07-19 2022-09-23 南京中医药大学 具有抗抑郁与抗老年痴呆症功效的组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1836687A (zh) * 2005-03-25 2006-09-27 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083932A (en) * 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
US7371416B2 (en) * 2005-04-12 2008-05-13 You-Sup Chung Method for preparing processed ginseng to obtain increased amount of ginsenoside RG5

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1836687A (zh) * 2005-03-25 2006-09-27 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CH'UN-HSING CHANG: "Modern Psychology", WORLD HEALTH ORGANIZATION
See also references of EP2216040A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533535A (ja) * 2009-07-16 2012-12-27 シージェイ チェイルジェダン コーポレーション ジンセノサイド濃縮画分を含む血圧降下用組成物
AU2016256704B2 (en) * 2012-08-15 2018-08-02 Chi, Yu Fen Pharmaceutical composition increasing cyclic AMP content and availability in vivo, and preparation method thereof

Also Published As

Publication number Publication date
CA2746663A1 (en) 2009-06-11
JP2011504887A (ja) 2011-02-17
EP2216040A1 (en) 2010-08-11
BRPI0722182A2 (pt) 2014-04-08
US20100311674A1 (en) 2010-12-09
EP2216040A4 (en) 2011-06-15
JP5628682B2 (ja) 2014-11-19
AU2007361992A1 (en) 2009-06-11
ZA201004033B (en) 2011-08-31
AU2007361992B2 (en) 2013-07-18
MX2010005840A (es) 2010-10-07
IL206082A0 (en) 2010-11-30
KR20100091206A (ko) 2010-08-18

Similar Documents

Publication Publication Date Title
WO2009070915A1 (en) Pharmaceutical compositions for treating depression and anxiety
CN100509006C (zh) 治疗抑郁症的药物组合物及其制法
EP2491934B1 (en) Use of albiflorin for anti-depression
WO2009070924A1 (en) Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
CN105920476B (zh) 防治阿尔茨海默病中药组合物及其制备方法
EP2644198B1 (en) Antianxiety and sleep disorder improving use of albiflorin
WO2011003226A1 (zh) 治疗抑郁症的药物组合物、制备方法及用途
WO2009070921A1 (en) Antimelancholic medicine prepared with jujube camp materials
US20230125425A1 (en) Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof
CN101450103A (zh) 用于治疗忧郁症及焦虑症的药物组合物
CN104548020B (zh) 一种药物组合物在制备治疗老年痴呆症药物中的用途
WO2009070922A1 (fr) Compositions pharmaceutiques pour le traitement de l&#39;anxiété
CN103768171A (zh) 抗抑郁、杀菌消炎的中药组合物及其制备方法
KR102226052B1 (ko) 항스트레스, 항우울 및 항불안 효과를 갖는, 테아닌과 벌화분 배합물
TW200920391A (en) Multi-target post-receptor action used in pharmaceutical composition for depression treatment
WO2009070923A1 (fr) Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation
TWI400078B (zh) 以甘草、大棗為原料的治療憂鬱症的藥物組合物
RU2452505C2 (ru) Фармацевтические композиции с механизмом многоцелевого рецепторного противодействия для лечения депрессии
TWI394576B (zh) 以人參、大棗為原料的治療憂鬱症的藥物組合物及其製法
CN101450062A (zh) 多靶标受体后作用机制用于治疗忧郁症的药物组合物
WO2009070917A1 (fr) Composition pharmaceutique orale pour le traitement de la barythymie
TWI453027B (zh) 主功效成分為大棗環腺苷單磷酸之藥物作為治療憂鬱症的用途
CN103919875A (zh) 用于治疗忧郁症及焦虑症的药物组合物的制备方法
RU2449804C2 (ru) Фармацевтические композиции для лечения депрессии и тревожного расстройства (варианты)
CN111529585A (zh) 改善抑郁症伴随勃起功能障碍的中药组合物及其制备方法和应用

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845763

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1925/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/005840

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007845763

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 206082

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 20107012032

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010535193

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007361992

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010121521

Country of ref document: RU

Ref document number: 10079497

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2007361992

Country of ref document: AU

Date of ref document: 20071130

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12745459

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2746663

Country of ref document: CA

ENP Entry into the national phase

Ref document number: PI0722182

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100531